Activity heats up around Australian pharma pricing deal
This article was originally published in SRA
Research-based drug industry association Medicines Australia has written to a senate committee urging that the Parliament should pass before 1 October a medicines pricing deal bill that aims to save taxpayers Aus$1.9 billion (US$1.7 billion) over a five-year period1-4. The Generic Medicines Industry Association (GMiA), meanwhile, has written to the same committee arguing against implementing the deal.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.